Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Editas Medicine

RFK Jr. Just Supercharged These 2 Biotech Penny Stocks

SGMO and EDIT are set to benefit from RFK Jr.’s plans to fast-track the review of drugs targeting rare diseases.

Editas Medicine Presents Data From RUBY Trial At ASH 2024, Showing Reni-Cel Achieves 96% VOE-Free Rate, Sustained Increases In Hemoglobin And Fetal Hemoglobin, And Clinically Meaningful Pain And Function Improvements In Severe Sickle Cell Patients; Safety Profile Consistent With Myeloablative Conditioning

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual MeetingGlobe NewswirePoster presentation at ASH

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Editas Medicine's Return On Capital Employed Insights

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.

Expert Ratings for Editas Medicine

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:

Editas Medicine: Q1 Earnings Insights

Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know

Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to access the live webcast.

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Editas Medicine

Expert Ratings For Editas Medicine

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:

Organisations

B of A Securities

Charter Communications

CyberArk Software

Range Resources

Canadian Natural Res

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

294,423 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play